PARP inhibitors for prostate cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) blues Editorial

  

Authors:	Beije, N.; Abida, W.; Antonarakis, E. S.; Castro, E.; de Wit, R.; Fizazi, K.; Gillessen, S.; Hussain, M.; Mateo, J.; Morris, M. J.; Olmos, D.; Sartor, O.; Sharp, A.; Sweeney, C. J.; de Bono, J. S.
Title:	PARP inhibitors for prostate cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) blues
Keywords:	signal transduction; overall survival; gene deletion; genetics; antineoplastic agent; dna repair; progression free survival; gene expression; editorial; brca1 protein; brca2 protein; prostate cancer; homozygote; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; down regulation; castration resistant prostate cancer; parp inhibitor; castration-resistant prostate cancer; metastatic prostate cancer; recombination repair; intention to treat analysis; humans; human; male; circulating tumor dna; prostatic neoplasms, castration-resistant; metastatic castration resistant prostate cancer; poly(adp-ribose) polymerase inhibitors; androgen receptor signalling inhibitor
Journal Title:	European Urology
Volume:	84
Issue:	3
ISSN:	0302-2838
Publisher:	Elsevier Science, Inc.
Date Published:	2023-09-01
Start Page:	253
End Page:	256
Language:	English
DOI:	10.1016/j.eururo.2023.03.038
PUBMED:	37087376
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85153239636&doi=10.1016%2fj.eururo.2023.03.038&partnerID=40&md5=4d68316774065a580d44d2b79020325d
Notes:	Editorial -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/208887